Mineralys Therapeutics, Inc. (MLYS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6031701013
Mineralys Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -170.60 m USD |
| EBIT | -154.65 m USD |
| Net income | -154.65 m USD |
| Diluted EPS – continuing operations | -2.29 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
More stocks
- Inmyshow Digital Technology Group Co Ltd (600556.SS)
- Hyundai Department (069960.KS)
- FIRST MID BANCSHARES, INC. (FMBH)
- Turning Point Brands, Inc. (TPB)
- INNODATA INC (INOD)
- HBT Financial, Inc. (HBT)
- Spire Healthcare Group PLC (SPI.L)
- Radware Ltd (RDWR)
- Eton Pharmaceuticals, Inc. (ETON)
- Ascentage Pharma Group International (AAPG)
- BOTH Engineering Technology Co. Ltd. A (601133.SS)
- Sakura Development Co Ltd (2539.TW)
Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.